Hannah Lee

I'll research this attorney's background and verify the case details before drafting.

Good material so far. Let me verify case outcomes and current status.

Specialty / focus areas. Hannah Lee is a patent litigator whose practice spans both technology and life sciences. Firm and conference bios describe work in pharmaceuticals and drug-delivery technology, semiconductors, computer security/networking software, and biotechnology/medical devices. That mix is consistent with the tracked matters, which are dominated by Centripetal Networks' cybersecurity and network-threat-detection patents (packet filtering, encrypted-traffic threat detection, decryption), alongside plaintiff-side pharmaceutical and Express Mobile software matters. Her technical background — a B.S. in chemical engineering — underlies the pharma side; the Centripetal docket (six of nine tracked appearances) is the Wi-Fi/network-security side. Note the tracked set shows no standard-essential-patent/FRAND work; the Wi-Fi flavor is network-security, not SEP licensing.

Side preference and firm context. The tracked docket is 9–0 on the plaintiff/asserting side, but that reflects the Centripetal engagement far more than a general posture: six of the nine appearances involve Centripetal Networks as the patent owner asserting against Cisco, Keysight, and (as patent owner in the parallel IPRs/appeals) Palo Alto Networks. Firm materials describe her as representing both plaintiffs and defendants, and her Purdue Pharma engagement was plaintiff-side while at Kramer Levin. Firm history: she began at Perkins Coie, moved with the Paul Andre/Lisa Kobialka team to King & Spalding, and joined Kramer Levin in October 2011 to help open its Silicon Valley (Redwood Shores) office, making partner there in October 2019. Per her own alumni account and Genentech-side sources, she left Kramer Levin in 2024 for Genentech, where she is in-house counsel handling patent litigation and related risk/policy work — so the tracked "Kramer Levin" affiliation is historical, not current. (Kramer Levin later combined with Herbert Smith Freehills in June 2025; her practice group's leadership subsequently moved to Brown Rudnick, which does not appear to involve her.)

Notable cases and outcomes. Her most prominent matter is Centripetal Networks, Inc. v. Cisco Systems, Inc. (E.D. Va.), where she was part of the trial team that tried the case as the first federal virtual bench trial and obtained an October 2020 finding of willful infringement of four network-security patents, with damages of roughly $755.8M enhanced 2.5x to a total award of about $1.9B — among the largest patent awards ever. That judgment was vacated by the Federal Circuit in June 2022 (No. 2020-2063) because the trial judge's spouse held Cisco stock, with remand to a new judge; the award therefore did not stand. Additional tracked work includes the related Centripetal v. Keysight and Palo Alto Networks v. Centripetal litigation and appeals, and Express Mobile, Inc. v. Google LLC (tracker lists her as Of Counsel for the plaintiff). An earlier bio credits her as senior associate managing a drug-delivery patent case for a specialty pharmaceutical client that produced a $62M settlement against Purdue Pharma. One tracked appearance is uncaptioned and shows her as withdrawn trial counsel.

PTAB / IPR and credentials. She has substantial IPR experience, including serving as lead counsel in three IPRs in which all 25 challenged claims of two patents were sustained, and she has litigated PTAB matters in the Centripetal/Keysight, Cisco, and Palo Alto Networks proceedings, including appeals. Her post-Cisco-IPR appeals have gone largely against her client on validity, but the Federal Circuit has twice faulted Board procedure or analysis in those cases (vacating a Palo Alto Networks final written decision in October 2025 for failure to weigh copying evidence; affirming in 2026 that Keysight forfeited arguments on certain dependent claims), so the procedural rulings have cut both ways. Bar: admitted in California (appeared pro hac vice in E.D. Va.). Education: B.S., Stanford University (chemical engineering, 2003); J.D., Northwestern University School of Law.

Caveat: the two uncaptioned tracked entries cannot be verified from public sources, and the case-level outcomes above are drawn from court opinions and Law360/IPWatchdog reporting; the current Genentech role is sourced to firm alumni materials and third-party org-chart data rather than a company press release.